Voiant
Voiant and Thirona have announced they have entered a global commercial partnership, combining Voiant's expertise in supporting clinical trials in pulmonary drug and treatment development with Thirona's expertise in advanced lung image analysis.
Building further on several years of cooperation, the two companies are now formally joining forces to provide full scope integral services for clinical trials with AI-powered lung image analysis.
With AI imaging playing an increasingly important role in clinical trials, companies recognise the market need for highly reliable integrated solutions supporting clients in imaging-based trials. The companies say that ensuring a robust quality assurance process along the whole trial is critical to deliver reliable and accurate outcomes, minimising the risk of trial failure and saving on developmental costs.
"Our integrated platform efficiently meets comprehensive pulmonary research needs. Together, we offer rapid and reliable delivery of precise image endpoints for lung diseases," says Jim Primerano, CEO at Voiant.
Primerano added: "With Voiant's network of over 400 certified sites and Thirona's robust algorithm suites, our integrated platform efficiently meets comprehensive pulmonary research needs. Together, we offer rapid and reliable delivery of precise image endpoints for lung diseases."
"Imaging offers enormous new possibilities in drug and treatment development, but it requires solid experience to do it right and efficiently. Voiant's operational expertise and capabilities in managing complex imaging workflows form a perfect match with our competences in AI-powered lung image analysis," said Eva van Rikxoort, founder and CEO of Thirona.
